Important: VAERS reports alone cannot determine if a vaccine caused an adverse event. Reports may contain incomplete, inaccurate, or unverified information. Correlation does not equal causation.
#2179 most reported symptom for this vaccine
Capillary nail refill test abnormal has been reported 3 times in association with Tdap (Boostrix) vaccination in VAERS. This represents 0.0% of all 52,846 reports for this vaccine.
Among these reports, 1 mentioned death (33.33%) and 1 involved hospitalization (33.3%).
Capillary nail refill test abnormal is the #2179 most frequently reported symptom for Tdap (Boostrix) out of 2243 total symptoms.
Disclaimer: VAERS reports describe events that occurred after vaccination but do not establish that the vaccine caused the event. Many reported symptoms may be coincidental or related to underlying conditions.
Seeing 3 reports of Capillary nail refill test abnormal after Tdap (Boostrix) vaccination may seem alarming, but context is critical.
The 33.33% mortality rate among these reports is elevated, but this reflects the severity of the condition itself rather than vaccine causation.
This data comes from the Vaccine Adverse Event Reporting System (VAERS), jointly managed by CDC and FDA.